Oryzon Panel Discussion: Targeting LSD1 in CNS & Oncology
About The Event
Register to watch the replay.
Watch the replay here from the virtual panel discussion with Oryzon Genomics, featuring industry experts, discussing the unmet medical needs in specific CNS and oncology diseases, such as Borderline Personality Disorder, Schizophrenia, and Acute Myeloid Leukemia, along with Oryzon’s therapeutic strategy to treat the underlying causes of these diseases by targeting lysine specific demethylase 1 (LSD1), a key target for epigenetic regulation of gene expression.
The event highlighted Oryzon’s Phase 2 programs: vafidemstat, an LSD1 inhibitor optimized for CNS and psychiatric disorders, and iadademstat, a selective LSD1 inhibitor for oncology.